AIDS Home > Rescriptor and Pregnancy
Clinical studies on Rescriptor and pregnancy show that the medication increased the risk of heart-related birth defects. It also caused miscarriages and decreased the survival of newborns when it was given to pregnant animals. If you are taking Rescriptor and pregnancy occurs, your healthcare provider will weigh the benefits and possible risks before making a recommendation in your situation.
Rescriptor® (delavirdine mesylate) is a prescription medicine used to treat AIDS and HIV. Because it has not been adequately studied in pregnant women, it is not known whether Rescriptor is safe for use during pregnancy. However, in some circumstances, the benefits of the drug may outweigh the potential risks.
The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been studied in pregnant humans but that do appear to cause harm to the fetus in animal studies. Also, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating. While there have been no adequate studies of Rescriptor in pregnant woman, the drug has been studied in pregnant animals.
When given to pregnant rats, Rescriptor increased the risk of heart-related birth defects and decreased the survival of newborn rats. In pregnant rabbits, the drug caused miscarriages.
However, it is important to note that animals do not always respond to medicines the same way that humans do. Therefore, a pregnancy Category C medicine may be given to a pregnant woman if the healthcare provider believes that the benefits to the woman outweigh any possible risks to the unborn child.